Form 4: Vaxcyte COO Jim Wassil Reports Stock Transactions

Vaxcyte's Chief Operating Officer, Jim Wassil, reports multiple transactions involving the company's common stock and stock options.

Summary

• Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc., filed a Form 4 detailing several transactions involving the company's stock.
• On February 27, 2025, Wassil acquired 21,726 shares of common stock through restricted stock units (RSUs) at $0.
• On February 28, 2025, he acquired 5,649 shares via RSUs in lieu of a cash bonus at a price of $73.02.
• Also on February 28, 2025, Wassil surrendered 2,869 and 1,270 shares to cover tax withholding obligations at $73.02.
• On March 3, 2025, Wassil exercised options to acquire 2,638 shares at $2.42 and 5,362 shares at $5.35.
• He also sold 5,915 shares at a weighted average price of $73.071 and 2,085 shares at a weighted average price of $73.837.
• Additionally, on March 3, 2025, 3,015 shares were surrendered to the issuer to cover applicable tax withholding obligations at $72.1.
• Wassil also acquired 72,536 stock options at $74.22 on February 27, 2025.
• The sales reported on Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While there are sales, they are conducted under a pre-arranged plan and alongside acquisitions, suggesting a balanced view.

Positives

• The acquisition of shares through RSUs and option exercises demonstrates the executive's belief in the company's future.

Negatives

• The sale of shares, even under a 10b5-1 plan, could be interpreted negatively by some investors.

Risks

• Executive stock sales, even if pre-planned, can sometimes create uncertainty in the market.
• Tax obligations can drive sales regardless of the executive's long-term outlook.

Future Outlook

The vesting schedule of the RSUs and stock options suggests a continued commitment by the COO to the company's long-term success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options and RSUs to align management's interests with those of shareholders.
• The vesting schedules and exercise prices are typical for the biotechnology industry, where long-term growth is prioritized.
• The use of Rule 10b5-1 trading plans is a standard practice among public company executives to manage their stock holdings.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, depending on their interpretation of the insider activity.
• Employees may view the vesting of RSUs and option exercises as a positive sign of company performance.

Key Dates